GlycoEra AG

A small lab with an outsized ambition

Right now, in a lab on Einsiedlerstrasse in Wädenswil and an office near Boston, roughly thirty people are trying to do something the drug industry has mostly worked around for decades: not quiet the immune system, but reach into the blood and pull out the exact proteins making people sick.

GlycoEra AG is a clinical-stage biotech. It does not make a consumer app, a chip, or a productivity tool. It makes molecules - bifunctional biologics designed to find a harmful protein in circulation and escort it to the cell's recycling bin. The company is young, deliberately narrow, and unusually well funded for its size, with roughly $179 million raised and a who's-who of life-science investors on the cap table.

Four numbers that fit on a napkin and still explain most of the story.

Autoimmune disease is friendly fire

In autoimmune disease, the body's defense system mistakes its own tissue for an enemy. The standard response from medicine has been blunt: turn the whole system down. Immunosuppressants and broad biologics work, sometimes well, but they leave patients more exposed to infection and side effects. It is a bit like dealing with one rowdy guest by cutting the power to the entire building.

The culprits, in many of these diseases, are specific circulating proteins - autoantibodies that drift through the blood attacking the wrong target. A particularly stubborn class is pathogenic IgG4, implicated in pemphigus, muscle-specific kinase (MuSK) myasthenia gravis, primary membranous nephropathy, and autoimmune encephalitis. They are hard to remove cleanly, hard to remove deeply, and hard to remove without taking out the good antibodies too.

That is the tension running through everything GlycoEra does. Depth versus selectivity. Speed versus safety. Remove enough of the bad protein to actually help, without the collateral damage that makes existing therapies a trade-off.

A band that had played together before

GlycoEra was spun out of LimmaTech Biologics in 2021, but its real origin is older. Co-founders Amir Faridmoayer, Veronica Gambillara Fonck, and Dominique N. Sirena had worked together for more than fifteen years - first at GlycoVaxyn, a glycoengineering company acquired by GSK, then at LimmaTech. GlycoEra is, in effect, their third act with the same instrument: sugar chemistry.

Their bet was that glycans - the sugar structures decorating proteins - could be engineered not just to make better vaccines, but to control where a protein goes inside the body. Attach the right glycan to a molecule that grabs a harmful antibody, and you can direct that antibody to the lysosome, the cell's degradation machinery, where it is broken down for good.

The same three names keep appearing on the same letterhead. In biotech, that kind of band loyalty is rarer than it sounds.

From spinout to clinic-bound

A valet service for bad antibodies

GlycoEra calls its molecules extracellular protein degraders - in the field, the broader idea goes by names like G-LyTACs (glycan-based lysosome-targeting chimeras). The mechanics are easier than the acronyms. One end of the molecule binds the harmful protein. The other end, engineered with a specific glycan, engages a receptor that hauls the whole complex inside the cell and delivers it to the lysosome for destruction.

The platform is, in principle, indifferent to disease. Anything driven by a circulating protein is a candidate target. That breadth is the upside. The discipline is choosing where to start.

GE8820 - the lead program

GlycoEra started with pathogenic IgG4. GE8820 is designed to degrade IgG4 autoantibodies with a speed, depth, and selectivity the company argues current modalities cannot match - and, crucially, without immunosuppression. The same pathogenic IgG4 sits behind pemphigus, MuSK myasthenia gravis, primary membranous nephropathy, and autoimmune encephalitis, which means one program could open several doors.

A second program is in the works, with the company signalling it could file to begin trials for a second drug as soon as 2026. The strategy is recognizable: prove the platform once, convincingly, then let it compound.

Money is a vote, not a verdict

GlycoEra has not yet reported clinical results - it is, after all, only now heading into patients. So the strongest external evidence is who is willing to fund the attempt. In November 2021 the company raised CHF 45 million (US$49 million) in Series A. In May 2025 it closed an oversubscribed $130 million Series B led by Novo Holdings, with Catalio Capital Management, LifeArc Ventures and QIA joining alongside returning backers Sofinnova Partners, 5AM Ventures, Roche Venture Fund and Bristol Myers Squibb.

The investor list is the tell. Strategic arms of Roche and Bristol Myers Squibb do not write checks into platforms they think will go nowhere. A sovereign fund (QIA) and a dedicated life-science crossover (Novo Holdings) leading the round suggests this is being underwritten as a serious shot, not a science experiment.

• Spun out of LimmaTech Biologics and funded by tier-one life-science investors within months.
• Series B oversubscribed - more demand than the round could absorb.
• Lead program GE8820 advancing toward clinical data in patients.
• Dual operations across Switzerland and the Boston biotech cluster.

Precision, not suppression

GlycoEra's stated mission is to treat autoimmune disease by selectively degrading the circulating proteins that drive it - enabling earlier intervention and better outcomes without broad immune suppression. The vision behind it is plainer still: a future where precision protein degradation changes how these diseases are treated at all.

It is worth being honest about where things stand. GlycoEra is pre-product. The science is promising and the funding is real, but the proof that matters - patients who do better - is still ahead. The company is selling a hypothesis backed by credible people, not a track record of approvals. That is true of every clinical-stage biotech, and it is the part skeptics should keep in view.

If it works, the building keeps its lights on

If GlycoEra is right, the implications run past any single drug. A platform that can selectively remove a chosen circulating protein is, in theory, a tool for a long list of diseases - autoimmune today, possibly neurological and beyond later. The prize is not just a better myasthenia gravis treatment. It is a different default: target the cause, not the whole system.

Back in that Wädenswil lab and the office near Boston, the work is unglamorous - assays, doses, regulatory filings, the slow grind of turning a mechanism into a medicine. But the thing those thirty-odd people are chasing is simple to state. Find the protein making someone sick. Remove it. Leave everything else alone.

Figures and milestones drawn from public company announcements and press coverage. Funding totals are approximate; GlycoEra is clinical-stage and pre-product.